trending Market Intelligence /marketintelligence/en/news-insights/trending/sq_bxlp2clpnf6bl7kdchw2 content esgSubNav
In This List

Juno, Wuxi joint venture raises $90M to fund CAR-T cell therapy

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Juno, Wuxi joint venture raises $90M to fund CAR-T cell therapy

JW Therapeutics said it completed a $90 million series A funding round led by investors including Temasek, Sequoia Capital China, and YuanMing Capital.

The Shanghai-based company is a joint venture created by Celgene Corp.-owned Juno Therapeutics Inc. and, China's WuXi AppTec Co., Ltd.

The venture is developing a chimeric antigen receptor T-cell, or CAR-T cell, therapy, JWCAR029, for treating blood cancers such as diffuse large B-cell lymphoma.

The investor consortium also included Oriza Seed Capital, Yipu Capital, AVICT Global Holdings, and existing investors WuXi AppTec Group and Juno Therapeutics.